Autopsy report · NCT01824303
Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
Cause of deathFunding or business
“This study was terminated early due to company decision.”
Life of this trial
- Ran for about 1 year 9 months before it stopped.
- 31 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Allergan
- Sponsor type
- Industry
- Conditions
- Interstitial Cystitis
- Interventions
- LiRIS 400 mg; LiRIS Placebo
- Participants
- 31
- Sites
- 17
- Countries
- Canada, United States
Trials that died the same way
- PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
“The study was terminated early due to company decision.” - Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
“The study was terminated due to a business decision.” - Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
“The study terminated early because the company was longer providing the investigational product.” - Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase
“This study was terminated early for administrative reasons.” - An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths
“Due to a business decision to stop the project, the study was terminated early.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.